Get the Stockscreener App
4.78
6.70%
0.30
After Hours:
4.69
-0.09
-1.88%
Dermata Therapeutics Inc stock is traded at $4.78, with a volume of 1.73M.
It is up +6.70% in the last 24 hours and down -9.13% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$4.48
Open:
$4.54
24h Volume:
1.73M
Relative Volume:
15.03
Market Cap:
$3.26M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.2232
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
-6.82%
1M Performance:
-9.13%
6M Performance:
-42.95%
1Y Performance:
-65.11%
1-Day Range:
$4.54
$5.18
1-Week Range:
$4.22
$5.87
52-Week Range:
$4.22
$23.70
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
4.78 | 3.05M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
What drives Dermata Therapeutics Inc stock priceMarket Correction Analysis & Low Risk Investment Tips - earlytimes.in
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket - Benzinga
News impact scoring models applied to Dermata Therapeutics Inc. Equity Warrant2025 Price Momentum & Smart Money Movement Tracker - newser.com
What the charts say about Dermata Therapeutics Inc. Equity Warrant today2025 Fundamental Recap & Smart Allocation Stock Tips - newser.com
Is Dermata Therapeutics Inc. Equity Warrant stock a top pick in earnings seasonMarket Sentiment Report & Community Verified Trade Alerts - newser.com
Why Dermata Therapeutics Inc. Equity Warrant stock is a must watch in 2025Market Growth Summary & Real-Time Chart Breakout Alerts - newser.com
Why Dermata Therapeutics Inc. stock could outperform in 20252025 Market Trends & Risk Adjusted Swing Trade Ideas - newser.com
Measuring Dermata Therapeutics Inc. Equity Warrant’s beta against major indicesJuly 2025 Outlook & Weekly High Return Stock Opportunities - newser.com
What momentum shifts mean for Dermata Therapeutics Inc. Equity WarrantWeekly Trade Analysis & Consistent Profit Trade Alerts - newser.com
How buybacks impact Dermata Therapeutics Inc. Equity Warrant stock value2025 Investor Takeaways & Weekly Consistent Profit Watchlists - newser.com
Psyence Biomedical Stock Price, Quotes and Forecasts | NASDAQ:PBM - Benzinga
Advanced analytics toolkit walkthrough for Dermata Therapeutics Inc.Long Setup & Weekly Setup with ROI Potential - newser.com
Why Dermata Therapeutics Inc. stock remains a top recommendation2025 Geopolitical Influence & Accurate Buy Signal Alerts - newser.com
Australian patent office accepts Dermata’s acne treatment patent By Investing.com - Investing.com Canada
Australian patent office accepts Dermata’s acne treatment patent - Investing.com Australia
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office - Yahoo Finance
Primary Axillary Hyperhidrosis Pipeline 2025: Key Clinical - openPR.com
Primary Axillary Hyperhidrosis Pipeline 2025: Key Clinical Developments By 5+ Global Leaders Delveinsight Featuring Brickell Biotech Inc., Dermata Therapeutics LLC, Dr. August Wolff Gmbh & Co. KG - Menafn.com
Can swing trading help recover from Dermata Therapeutics Inc. losses2025 Market Overview & Long-Term Growth Stock Strategies - newser.com
Real time breakdown of Dermata Therapeutics Inc. stock performance2025 Major Catalysts & Smart Money Movement Alerts - newser.com
ProShares Trust ProShares Ultra Consumer Staples Stock Analysis and ForecastVolatility Adjusted Trading & Minimal Investment Capital Gains - earlytimes.in
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):